Tag: Simcyp
Simcyp:20 年的创新
Simcyp 时间轴:20 年的创新
SIVA V3:Simcyp 体外数据分析工具箱
The SIVA Toolkit is a user-friendly platform, specifically designed to assist scientists
with the analysis of complex in vitro studies using whole cells, tissue samples, and solid
dosage forms to assess the exposure, metabolism, transport, and dissolution/solubility
of drugs.
Certara Launches New Version of Simcyp® Simulator for Population-Based Pharmacokinetic Modeling and Simulation
Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development
Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc.
PRINCETON, NJ – Feb. 25, 2020 – Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease.
如何证明复杂皮肤仿制药的虚拟生物等效性
This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive dermal model— MPML MechDermA, a multi-phase, multi-dimensional dermal absorption model.
Certara Partners with Galderma to Attain FDA Approval of AKLIEF® Topical Acne Cream
PRINCETON, NJ – Jan. 8, 2020 – Certara’s Simcyp® Simulator’s MechDermA™ model provided safety label claim and pediatric dosing information without the need for testing in clinical patients for a topical drug product.
Updates to the Simcyp Simulator’s Oral Absorption ADAM and M-ADAM Models
This webinar provided an update on the extensive recent additions to the mechanistic models for handling oral dosage forms available within the ADAM/M-ADAM framework.
LEO Pharma Joins Certara’s PBPK Simcyp Simulator Consortium
PRINCETON, NJ – Dec. 10, 2019 – LEO Pharma has licensed Certara’s proprietary Simcyp®️ Population-based Simulator and joined its Consortium.